CN103463122A - 一种复方氟尿嘧啶注射液及其制备方法 - Google Patents
一种复方氟尿嘧啶注射液及其制备方法 Download PDFInfo
- Publication number
- CN103463122A CN103463122A CN2013104390219A CN201310439021A CN103463122A CN 103463122 A CN103463122 A CN 103463122A CN 2013104390219 A CN2013104390219 A CN 2013104390219A CN 201310439021 A CN201310439021 A CN 201310439021A CN 103463122 A CN103463122 A CN 103463122A
- Authority
- CN
- China
- Prior art keywords
- liquid
- injection
- unit
- preparation
- full dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 98
- 229940081995 fluorouracil injection Drugs 0.000 title claims abstract description 96
- 238000002360 preparation method Methods 0.000 title claims abstract description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 103
- 229940090044 injection Drugs 0.000 claims abstract description 56
- 238000002347 injection Methods 0.000 claims abstract description 56
- 239000007924 injection Substances 0.000 claims abstract description 56
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims description 327
- 239000000872 buffer Substances 0.000 claims description 79
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 54
- 239000000787 lecithin Substances 0.000 claims description 54
- 235000010445 lecithin Nutrition 0.000 claims description 54
- 229940067606 lecithin Drugs 0.000 claims description 54
- 229910052799 carbon Inorganic materials 0.000 claims description 49
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 48
- 238000004321 preservation Methods 0.000 claims description 48
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 38
- 238000004945 emulsification Methods 0.000 claims description 33
- 239000008215 water for injection Substances 0.000 claims description 33
- 230000001804 emulsifying effect Effects 0.000 claims description 31
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 28
- 229960002949 fluorouracil Drugs 0.000 claims description 28
- 238000010438 heat treatment Methods 0.000 claims description 28
- 239000000706 filtrate Substances 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 23
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 22
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 22
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 22
- 241000208340 Araliaceae Species 0.000 claims description 21
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 21
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 21
- 235000008434 ginseng Nutrition 0.000 claims description 21
- 150000004676 glycans Chemical class 0.000 claims description 21
- 239000002502 liposome Substances 0.000 claims description 21
- 229920001282 polysaccharide Polymers 0.000 claims description 21
- 239000005017 polysaccharide Substances 0.000 claims description 21
- 230000001954 sterilising effect Effects 0.000 claims description 21
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 20
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 20
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 20
- 239000005642 Oleic acid Substances 0.000 claims description 20
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 20
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 20
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 20
- 235000021313 oleic acid Nutrition 0.000 claims description 20
- 235000012000 cholesterol Nutrition 0.000 claims description 19
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 18
- 229920000053 polysorbate 80 Polymers 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 17
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- 239000000839 emulsion Substances 0.000 claims description 16
- 238000002844 melting Methods 0.000 claims description 16
- 230000008018 melting Effects 0.000 claims description 16
- 238000005374 membrane filtration Methods 0.000 claims description 16
- 239000008363 phosphate buffer Substances 0.000 claims description 16
- 238000007670 refining Methods 0.000 claims description 16
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 14
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 14
- 235000019800 disodium phosphate Nutrition 0.000 claims description 14
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 12
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 12
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 150000003904 phospholipids Chemical class 0.000 claims description 10
- 238000004090 dissolution Methods 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 4
- 230000002045 lasting effect Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 3
- 238000005538 encapsulation Methods 0.000 abstract description 5
- 238000000034 method Methods 0.000 description 19
- 239000002245 particle Substances 0.000 description 18
- 210000000481 breast Anatomy 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 229930003231 vitamin Natural products 0.000 description 10
- 239000011782 vitamin Substances 0.000 description 10
- 229940088594 vitamin Drugs 0.000 description 10
- 235000013343 vitamin Nutrition 0.000 description 10
- 150000003722 vitamin derivatives Chemical class 0.000 description 10
- 102000002322 Egg Proteins Human genes 0.000 description 7
- 108010000912 Egg Proteins Proteins 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 210000004681 ovum Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 150000003016 phosphoric acids Chemical class 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 description 5
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 3
- 206010070863 Toxicity to various agents Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000007981 phosphate-citrate buffer Substances 0.000 description 3
- FYKDNWHPKQOZOT-UHFFFAOYSA-M sodium;dihydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OP(O)([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FYKDNWHPKQOZOT-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- QMYTXCUSWCFXLY-UHFFFAOYSA-N methanol;triethylazanium;hydroxide Chemical compound [OH-].OC.CC[NH+](CC)CC QMYTXCUSWCFXLY-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
平均包封率 | RSD | |
样品1 | 70.5% | 1.61% |
样品2 | 67.6% | 1.67% |
样品3 | 66.4% | 1.72% |
样品4 | 74.8% | 1.78% |
样品5 | 68.2% | 1.73% |
样品6 | 69.9% | 1.68% |
样品7 | 67.9% | 1.75% |
样品8 | 66.4% | 1.68% |
样品9 | 42.6% | 1.79% |
样品10 | 44.2% | 1.68% |
样品11 | 54.7% | 1.65% |
峰# | 保留时间 | 面积 | 高度 | 面积% | 拖尾因子 | 分离度 | 相对保留时间 |
1 | 1.416 | 20951 | 459 | 1.081 | 0.536 | 0.000 | 0.000 |
2 | 1.750 | 6401 | 411 | 0.330 | 0.000 | 0.318 | 0.000 |
3 | 4.038 | 1910977 | 309862 | 98.589 | 1.795 | 0.758 | 0.000 |
总计 | 1938329 | 100.000 |
峰# | 保留时间 | 面积 | 高度 | 面积% | 拖尾因子 | 分离度 | 相对保留时间 |
1 | 1.254 | 4392 | 288 | 0.161 | 0.000 | 0.000 | 0.000 |
2 | 1.417 | 2161 | 408 | 0.079 | 0.000 | 0.000 | 0.000 |
3 | 1.722 | 10112 | 618 | 0.371 | 0.000 | 0.594 | 0.000 |
4 | 4.037 | 2710925 | 435156 | 99.389 | 1.801 | 0.866 | 0.000 |
总计 | 2727590 | 100.000 |
乳粒是否均匀 | 有无凝聚 | 平均乳粒直径 | |
样品1 | 均匀 | 无 | 0.155μm |
样品2 | 均匀 | 无 | 0.182μm |
样品3 | 均匀 | 无 | 0.164μm |
样品4 | 均匀 | 无 | 0.122μm |
样品5 | 均匀 | 无 | 0.136μm |
样品6 | 均匀 | 无 | 0.153μm |
样品7 | 均匀 | 无 | 0.148μm |
样品8 | 均匀 | 无 | 0.173μm |
样品9 | 均匀 | 无 | 0.351μm |
样品10 | 均匀 | 无 | 0.274μm |
样品11 | 均匀 | 无 | 0.245μm |
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310439021.9A CN103463122B (zh) | 2013-09-24 | 2013-09-24 | 一种复方氟尿嘧啶注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310439021.9A CN103463122B (zh) | 2013-09-24 | 2013-09-24 | 一种复方氟尿嘧啶注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103463122A true CN103463122A (zh) | 2013-12-25 |
CN103463122B CN103463122B (zh) | 2015-05-13 |
Family
ID=49788315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310439021.9A Active CN103463122B (zh) | 2013-09-24 | 2013-09-24 | 一种复方氟尿嘧啶注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103463122B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106581021A (zh) * | 2016-11-17 | 2017-04-26 | 浙江省医学科学院 | 苍术苷和5‑氟尿嘧啶联合在制备预防和治疗直肠癌药物中的应用 |
CN110898001A (zh) * | 2019-11-05 | 2020-03-24 | 黑龙江福和制药集团股份有限公司 | 一种耐低温的5-氟尿嘧啶注射液 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101991537A (zh) * | 2009-08-21 | 2011-03-30 | 华北制药集团制剂有限公司 | 一种复方氟尿嘧啶脂质体口服液及其制备方法 |
-
2013
- 2013-09-24 CN CN201310439021.9A patent/CN103463122B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101991537A (zh) * | 2009-08-21 | 2011-03-30 | 华北制药集团制剂有限公司 | 一种复方氟尿嘧啶脂质体口服液及其制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106581021A (zh) * | 2016-11-17 | 2017-04-26 | 浙江省医学科学院 | 苍术苷和5‑氟尿嘧啶联合在制备预防和治疗直肠癌药物中的应用 |
CN106581021B (zh) * | 2016-11-17 | 2020-04-21 | 浙江省医学科学院 | 苍术苷和5-氟尿嘧啶联合在制备预防和治疗直肠癌药物中的应用 |
CN110898001A (zh) * | 2019-11-05 | 2020-03-24 | 黑龙江福和制药集团股份有限公司 | 一种耐低温的5-氟尿嘧啶注射液 |
Also Published As
Publication number | Publication date |
---|---|
CN103463122B (zh) | 2015-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105853403B (zh) | 一种紫杉醇棕榈酸酯脂质体及其制备方法 | |
CN103120645A (zh) | 伊立替康或盐酸伊立替康脂质体及其制备方法 | |
CN109568297A (zh) | 一种二氢杨梅素固体脂质纳米粒及制备方法 | |
CN102357075A (zh) | 一种多西他赛纳米制剂及其制备方法 | |
CN101612121A (zh) | 紫杉醇微乳的制备方法 | |
CN102485212B (zh) | 苹果酸舒尼替尼脂质体及其制备方法 | |
CN103463122B (zh) | 一种复方氟尿嘧啶注射液及其制备方法 | |
CN107158395B (zh) | 一种卡巴他赛磷脂组合物及其制备方法和应用 | |
CN107137353A (zh) | 一种注射用卡巴他赛脂质体剂型及其制备方法 | |
CN103181897B (zh) | 吉非替尼脂质体制剂及其制备方法 | |
CN105534904B (zh) | 注射用多西他赛组合物及其制备方法 | |
CN112386586A (zh) | 一种白蛋白纳米粒的制备方法 | |
CN102451176B (zh) | 多西紫杉烷/类固醇复合物 | |
CN102028655B (zh) | 扎那米韦固体脂质纳米粒的口服制剂及其制备方法 | |
Le et al. | Anticancer efficacy of oral docetaxel nanoformulation for metronomic chemotherapy in metastatic lung cancer | |
CN110464708A (zh) | 一种螺旋藻纳米制剂及其制备方法 | |
Wang et al. | Safety evaluation of liposomal nanohybrid cerasomes and their application in the release of 10-hydroxycamptothecin | |
CN102961335B (zh) | 一种喜树碱类药物脂质体组合物及其制备方法 | |
CN111329838B (zh) | 一种紫杉醇脂质体药物组合物及其制备方法 | |
CN108498455A (zh) | 一种油性水溶药物纳米晶及其制备方法 | |
CN114788811A (zh) | 一种盐酸吉西他滨壳聚糖胶束及其制备方法 | |
CN101352418B (zh) | 吡柔比星或盐酸吡柔比星脂质纳米粒及其制备方法 | |
CN108721644B (zh) | 一种紫杉烷类药物脂质体制备方法 | |
CN112168788B (zh) | 静脉注射用阿瑞匹坦胶束无菌冻干制剂及其制备方法 | |
CN104825404A (zh) | 一种灯盏花素长效冻干微乳及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 110016 Liaoning city of Benxi Province Economic and Technological Development Zone Cladrastis Road No. 111 Patentee after: SHENYANG YAODA LEIYUNSHANG PHARMACEUTICAL CO.,LTD. Address before: 110016 Shenhe province Shenyang District Cultural Road, No. 103, No. Patentee before: SHENYANG YAODA PHARMACEUTICAL Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A kind of compound fluorouracil injection and preparation method thereof Effective date of registration: 20220921 Granted publication date: 20150513 Pledgee: Bank of China Limited Shenyang Tiexi sub branch Pledgor: SHENYANG YAODA LEIYUNSHANG PHARMACEUTICAL CO.,LTD. Registration number: Y2022210000144 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230918 Granted publication date: 20150513 Pledgee: Bank of China Limited Shenyang Tiexi sub branch Pledgor: SHENYANG YAODA LEIYUNSHANG PHARMACEUTICAL CO.,LTD. Registration number: Y2022210000144 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A compound fluorouracil injection and its preparation method Effective date of registration: 20230922 Granted publication date: 20150513 Pledgee: Bank of China Limited Shenyang Tiexi sub branch Pledgor: SHENYANG YAODA LEIYUNSHANG PHARMACEUTICAL CO.,LTD. Registration number: Y2023210000241 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |